Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02571036 · ClinicalTrials.gov registry record · Phase 1
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
A Phase 1 study, sponsored by Deciphera Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 282
- Enrollment target
NCT02571036 is a Phase 1 study that has completed, run by Deciphera Pharmaceuticals. The registered enrollment target is 282 participants.
The verdict
NCT02571036, a Phase 1 study, has completed, sponsored by Deciphera Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 282 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase, and an expansion phase. All active patients (from both dose-escalation and expansion phases) will then transition into an extension phase.
Interventions
- DRUG DCC-2618
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 282 participants |
| Start Date | 2015-11 |
| Est. Completion | 2022-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02571036
The ClinicalTrials.gov registry entry for NCT02571036 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 282 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Deciphera Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which DCC-2618 is the first listed.
NCT02571036 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02571036 about?
NCT02571036 is a clinical study titled "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies". This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study con...
What is the current status of trial NCT02571036?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 282 participants. The study started on 2015-11. Estimated completion is 2022-04-29.
What interventions are being tested in trial NCT02571036?
The interventions under investigation include: DCC-2618 (DRUG).
Who is sponsoring clinical trial NCT02571036?
This trial is sponsored by Deciphera Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.